Scholarlink

<p>Although most mutations in Epidermal Growth Factor Receptor (<i>EGFR</i>) found in non-small cell lung cancer (NSCLC) patients are targetable drivers, exon 20 insertions (ex20ins) represent a distinct and heterogeneous subgroup with differences in treatment outcomes and prognosis. Next Generation Sequencing (NGS) testing has played a key role in identifying ex20ins and associated co-alterations, enhancing our understanding of the complex biology within this group. Furthermore, new molecules recently developed, some of them still under investigation, are shown promising results in the clinical management of ex20ins patients. This review aims to give an update of the landscape of <i>EGFR</i> ex20ins, focusing on their molecular and clinical implications as well as on new treatment strategies emerging in clinical trials.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Landscape and clinical implications of EGFR exon 20 insertions in non-small cell lung cancer patients

  • 期刊论文

  • 发表日期：

    2025年4月4日

查看全文
  • Mónica Garzón-Ibáñez,
  • Roxana Reyes,
  • Miguel Ángel Molina-Vila,
  • Ivana Gabriela Sullivan

摘要

Although most mutations in Epidermal Growth Factor Receptor (EGFR) found in non-small cell lung cancer (NSCLC) patients are targetable drivers, exon 20 insertions (ex20ins) represent a distinct and heterogeneous subgroup with differences in treatment outcomes and prognosis. Next Generation Sequencing (NGS) testing has played a key role in identifying ex20ins and associated co-alterations, enhancing our understanding of the complex biology within this group. Furthermore, new molecules recently developed, some of them still under investigation, are shown promising results in the clinical management of ex20ins patients. This review aims to give an update of the landscape of EGFR ex20ins, focusing on their molecular and clinical implications as well as on new treatment strategies emerging in clinical trials.